- Home
- AIRJ vs OLMA Comparison
AIRJ vs OLMA Comparison
Compare AIRJ & OLMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIRJ
- OLMA
- Stock Information
- Founded
- AIRJ 2018
- OLMA 2006
- Country
- AIRJ United States
- OLMA United States
- Employees
- AIRJ N/A
- OLMA N/A
- Industry
- AIRJ
- OLMA Biotechnology: Pharmaceutical Preparations
- Sector
- AIRJ
- OLMA Health Care
- Exchange
- AIRJ NYSE
- OLMA Nasdaq
- Market Cap
- AIRJ 278.3M
- OLMA 299.7M
- IPO Year
- AIRJ N/A
- OLMA 2020
- Fundamental
- Price
- AIRJ $3.98
- OLMA $5.33
- Analyst Decision
- AIRJ Strong Buy
- OLMA Strong Buy
- Analyst Count
- AIRJ 1
- OLMA 4
- Target Price
- AIRJ $12.00
- OLMA $24.50
- AVG Volume (30 Days)
- AIRJ 108.0K
- OLMA 411.5K
- Earning Date
- AIRJ 08-22-2025
- OLMA 08-05-2025
- Dividend Yield
- AIRJ N/A
- OLMA N/A
- EPS Growth
- AIRJ N/A
- OLMA N/A
- EPS
- AIRJ 0.86
- OLMA N/A
- Revenue
- AIRJ N/A
- OLMA N/A
- Revenue This Year
- AIRJ N/A
- OLMA N/A
- Revenue Next Year
- AIRJ N/A
- OLMA N/A
- P/E Ratio
- AIRJ $4.78
- OLMA N/A
- Revenue Growth
- AIRJ N/A
- OLMA N/A
- 52 Week Low
- AIRJ $3.74
- OLMA $2.86
- 52 Week High
- AIRJ $11.60
- OLMA $16.62
- Technical
- Relative Strength Index (RSI)
- AIRJ 37.92
- OLMA 66.85
- Support Level
- AIRJ $4.36
- OLMA $4.40
- Resistance Level
- AIRJ $4.99
- OLMA $5.36
- Average True Range (ATR)
- AIRJ 0.31
- OLMA 0.29
- MACD
- AIRJ -0.08
- OLMA 0.07
- Stochastic Oscillator
- AIRJ 4.72
- OLMA 93.20
About AIRJ MONTANA TECHNOLOGIES CORP
AirJoule Technologies Corp is the developer of AirJoule, an atmospheric water harvesting technology that provides efficient and sustainable air dehumidification and pure water from air. AirJoule can also enable transformative HVAC products to help customers save money on their energy bills while reducing environmental impact.
About OLMA Olema Pharmaceuticals Inc.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.